drugset / Trial / NCT06299709

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

NCT06299709

Phase 1 Completed 34 enrolled Vertex Pharmaceuticals Incorporated
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the relative bioavailability, food effect, and dose proportionality of a granule formulation of VNZ/TEZ/D-IVA.

Timeline

Start
2024-03-13
Primary completion
2024-05-23
Completion
2024-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Vanzacaftor Small molecule Oral
Subject deutivacaftor Unknown Oral
Subject tezacaftor Other / unclassified Oral

Indications